Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands ...

What Happened? A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5% ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

Biogen Inc. closed 47.73% short of its 52-week high of $238.00, which the company reached on July 12th.

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual C-Suite Leaders Awards, which highlights leading local executives and their ...

Biogen Inc. closed 48.82% short of its 52-week high of $238.00, which the company reached on July 12th.

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher ...

Biogen (NASDAQ:BIIB) lowered its full-year outlook to reflect the impact of a $165 million upfront transaction payment to ...